knowledge -WSS

knowledge

author：leisure time 2025-09-30 20:46:57 - browse：876

A man enters the Regeneron Clinic at a monoclonal antibody treatment site in Pembroke Pines, Florida – politics and policy coverage from STAT — Regeneron agreed to price limits for a new Covid-19 drug that will be developed in partnership with the Department of Health and Human Services. CHANDAN KHANNA/AFP via Getty Images

WASHINGTON — A groundbreaking clause in a new deal between the Department of Health and Human Services and the pharmaceutical company Regeneron marks the first time the Biden administration has directly used its leverage to challenge drugmakers’ list prices, experts told STAT.

The contract between Regeneron and the government requires that the list price for a future monoclonal antibody drug to prevent Covid-19 is the same or lower in the United States as in other high-income countries. The release doesn’t explain which countries the government will be comparing prices with, or how pricing data will be determined.

The deal was part of the White House’s Project NextGen initiative, which includes $5 billion in new vaccines and therapies. HHS announced that it is spending $326 million to help Regeneron develop a new monoclonal antibody to prevent Covid-19. Regeneron in January announced plans to start testing a potentially variant-proof antibody, which is set to go into clinical trials later this year.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Moonlake's readout produced a cash windfall. Risks remain
Next article： Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

entertainment

focus

WSS

NEJM study link tiny plastics in blood vessels to heart problems

Amylyx ALS drug fails large clinical trial

Anthony Fauci pushes back on GOP claims during Covid hearing

Amylyx ALS drug failure raises questions and concerns

Elevance PBM president out as customers face prescription chaos

Air quality improving but still lags in Black, Hispanic communities

knowledge

knowledge

focus

State Dept. review finds Biden bears some blame for Afghanistan failures

What it’s like to watch children die of measles

United colonoscopy coverage change 'may cost lives,' doctors say

Illumina board agrees to spin off Grail, as divestment plans proceed

Jerome Adams on the need for new antivirals for Covid

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

New air purifier tech could be key to improving indoor air quality

Finland to offer bird flu vaccine to select groups of people, a possible global first

Bright Health sells Medicare Advantage business to Molina

Readout Newsletter: Amylyx, Alto Neuro, and Eli Lilly for the Oscars

knowledge

ASCO Takeaways: Winners, snoozers, and the art of cancer care

A new initiative will help leaders fight the next pandemic

The drug industry has found itself all alone in Washington

UnitedHealth CEO's Medicaid comments send insurer stocks diving

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

A new initiative will help leaders fight the next pandemic

entertainment

focus

explore

leisure time